newsfilter
← Latest News
GlobeNewswire·

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to